QBECO SSI

July 30, 2018July 30, 2018

Qu Biologics Recruiting Crohn’s Patients in Canada for Phase 2 Trial, Hosting Webinar

News

Qu Biologics has started enrolling patients in the RESTORE Phase 2 trial to evaluate its lead investigative immunotherapy, QBECO SSI, in patients with moderate to severe Crohn’s disease. The study ... Read more

April 23, 2018April 23, 2018

Investigational QBECO SSI Therapy Enters Phase 2 Clinical Trial for Crohn’s

News

Qu Biologics soon will begin recruiting participants for a Phase 2 clinical trial to continue investigating the company’s special platform of immunotherapies, collectively called Site Specific Immunomodulators (SSIs), as a potential ... Read more

October 5, 2017October 5, 2017

Genetic, Immune Biomarkers Can Help Predict Response to QBECO SSI Treatment, UC Trial Suggests

News

Detection of specific genetic alterations and immunological biomarkers can help predict the response to QBECO SSI immunotherapy in patients with inflammatory bowel disease (IBD). This finding resulted from the analysis ... Read more

October 30, 2014October 30, 2014

Qu Biologics Cleared to Proceed with Crohn’s Disease Clinical Trial, DSMC Says

Crohn's Disease, News

Qu Biologics, Inc., a biotech company that specializes in formulating Site Specific Immunomodulators (SSI) for the restoration of normal immune system function, has just announced that a Data Safety Monitoring Committee ... Read more